Insights into defective serological memory after acute lymphoblastic leukaemia treatment: The role of the plasma cell survival niche, memory B-cells and gut microbiota in vaccine responses
Acute lymphoblastic leukaemia (ALL) is the most common type of cancer in children, accounting for approximately 25% of childhood cancer cases. As a result of effective treatments over the past decades, paediatric ALL mortality has been greatly reduced. Chemotherapy, however, has a range of harmful side effects including the loss of protective antibodies against vaccine-preventable diseases. Since ALL survivors have an increased risk of health problems including organ insufficiencies, acquired vaccine-preventable infections subsequent to clinical remission could become life threatening to these individuals.
Source: Blood Reviews - Category: Hematology Authors: Shanie Saghafian-Hedengren, Ismael S öderström, Eva Sverremark-Ekström, Anna Nilsson Tags: Review Source Type: research
More News: Acute Leukemia | Acute Lymphoblastic Leukemia | Cancer | Cancer & Oncology | Cancer Vaccines | Chemotherapy | Childhood Cancer | Children | Hematology | Leukemia | Pediatrics | Vaccines